MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Authors:
Open Access
- 1 April 2022
- journal article
- review article
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
- Vol. 28 (2) , 150-163
Abstract
Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP21fk0210090)
- University of Sydney
- National Health and Medical Research Council of Australia (APP1053206, APP1196492, APP2001692, APP1107178, APP1108422)
This publication has 133 references indexed in Scilit:
- Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist?Journal of Clinical and Experimental Hepatology, 2017
- Moderate Exercise for Nonalcoholic Fatty Liver Disease.JAMA Internal Medicine, 2016
- Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver DiseaseClinical Gastroenterology and Hepatology, 2016
- Liver resection for hepatocellular carcinoma in patients with metabolic syndrome: A multicenter matched analysis with HCV-related HCCJournal of Hepatology, 2015
- Oxidative stress promotes pathologic polyploidization in nonalcoholic fatty liver diseaseJournal of Clinical Investigation, 2015
- Gefitinib and Luteolin Cause Growth Arrest of Human Prostate Cancer PC-3 Cells via Inhibition of Cyclin G-Associated Kinase and Induction of miR-630PLOS ONE, 2014
- HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durabilityGut, 2013
- Serum albumin level is a notable profiling factor for non‐B, non‐C hepatitis virus‐related hepatocellular carcinoma: A data‐mining analysisHepatology Research, 2013
- Skeletal muscle metabolism is a major determinant of resting energy expenditure.Journal of Clinical Investigation, 1990
- Genetic polymorphism of enzymes of alcohol metabolism and susceptibility to alcoholic liver diseaseMolecular Aspects of Medicine, 1988